Brought to you by 
Genzyme acquires Verigen AG for up to $50mm
05 May 2009
Executive Summary
Genzyme has acquired privately held Verigen AG (cell therapy for cartilage repair) for $10mm in cash. It may also pay earn-outs of up to $40mm over the next six years based on the achievement of development (BLA and US marketing approval) and sales milestones.
Deal Industry
- Medical Devices
-
Medical Devices
- Biomaterials
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genzyme acquires Verigen AG for up to $50mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice